News for LIAN Stock

LianBio Announces Voluntarily Delisting from Nasdaq LianBio Announces Completion of Strategic Review LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets LianBio Announces Departure of Chief Financial Officer LianBio Announces Departure of Chief Executive Officer LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023 LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023 LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China LianBio to Participate in Upcoming Investor Conferences LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients LianBio Promotes Pascal Qian to Chief Commercial Officer LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore LianBio Announces President and Chief Strategy Officer Departure LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update LianBio to Participate in Upcoming Investor and Industry Events LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients LianBio to Participate in June Investor Events CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update NANOBIOTIX Provides First Quarter Operational and Financial Update LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022 LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms LianBio Announces Formation of Scientific Advisory Board NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3 NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F LianBio’s Partner ReViral Enters into Acquisition Agreement with Pfizer LianBio Appoints Wei Wei Chen to Board of Directors LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022 LianBio Issues Statement Regarding the HFCAA LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 ReViral Appoints Brett Haumann as Chief Medical Officer LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results Citi Appointed Depositary Bank for LianBio’s Sponsored ADR Program LianBio Announces Pricing of Initial Public Offering